- Home
- KRON vs LUCD Comparison
KRON vs LUCD Comparison
Compare KRON & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- LUCD
- Stock Information
- Founded
- KRON 2017
- LUCD 2018
- Country
- KRON United States
- LUCD United States
- Employees
- KRON N/A
- LUCD N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KRON Health Care
- LUCD Health Care
- Exchange
- KRON Nasdaq
- LUCD Nasdaq
- Market Cap
- KRON 59.1M
- LUCD 49.0M
- IPO Year
- KRON 2020
- LUCD 2021
- Fundamental
- Price
- KRON $0.99
- LUCD $0.84
- Analyst Decision
- KRON Buy
- LUCD Strong Buy
- Analyst Count
- KRON 3
- LUCD 4
- Target Price
- KRON $1.63
- LUCD $3.63
- AVG Volume (30 Days)
- KRON 292.4K
- LUCD 277.7K
- Earning Date
- KRON 11-13-2024
- LUCD 11-13-2024
- Dividend Yield
- KRON N/A
- LUCD N/A
- EPS Growth
- KRON N/A
- LUCD N/A
- EPS
- KRON N/A
- LUCD N/A
- Revenue
- KRON $9,864,000.00
- LUCD $4,189,000.00
- Revenue This Year
- KRON $62.21
- LUCD $91.72
- Revenue Next Year
- KRON N/A
- LUCD $139.38
- P/E Ratio
- KRON N/A
- LUCD N/A
- Revenue Growth
- KRON 146.48
- LUCD 179.27
- 52 Week Low
- KRON $0.69
- LUCD $0.63
- 52 Week High
- KRON $1.60
- LUCD $1.58
- Technical
- Relative Strength Index (RSI)
- KRON 53.69
- LUCD 51.29
- Support Level
- KRON $0.92
- LUCD $0.80
- Resistance Level
- KRON $1.02
- LUCD $0.88
- Average True Range (ATR)
- KRON 0.05
- LUCD 0.05
- MACD
- KRON 0.00
- LUCD 0.01
- Stochastic Oscillator
- KRON 77.38
- LUCD 55.57
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.